I et outcome forsøg med patienter med betydende macrovaskulær sygdom var hyppigheden af alvorlig hjerteinsufficiens ved kombinationsbehandling med insulin 1, 6% højere med pioglitazon end med placebo.
In an outcome study of patients with pre-existing major macrovascular disease, the incidence of serious heart failure was 1.6% higher with pioglitazone than with placebo, when added to therapy that included insulin.